Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$149.52+3.19 (+2.18%)
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Non-GAAP Income Tax Provision: $3,797M in FY2025, down 3.3% from a year earlier.
Latest, FY2025
3,797
Period ended Dec 31, 2025
Change on a year earlier
-3.3%
3,928 in FY2024
History
5 years
Since FY2020
Sources
4
Documents cited below
Where the FY2025 figure comes from
“|| Income Tax Provision (Benefit) | 2,804 | (525 | ) (3) | (473 | ) (3) | 65 | (3) | (60 | ) (4) | (993 | ) | 3,797”
Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Reported in Form 8-K Table 2a.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Non-GAAP Income Tax Provision ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3,797 | -3.3% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 3,928 | +83.3% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | 2,143 | -32.0% | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2022 | Dec 31, 2022 | 3,150 | – | Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗ |
| FY2020 | Dec 31, 2020 | 2,066 | – | Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗ |
Cite this data
StockData. (2026). Merck Non-GAAP Income Tax Provision ($M), annual FY2020–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/nongaap-tax
See every metric in the Merck KPI table. Data updated Oct 26, 2026.